Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | completed | Phase 3 | 291 | NovoCure GmbHINDUSTRY | 18 |
| Mar 18, 2026 |
| clinicaltrials |
| NCT04948333 | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP | completed | Phase 3 | 199 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT02504372 | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)(PEARLS) | completed | Phase 3 | 1,177 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2026 | clinicaltrials |
| NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | completed | Phase 3 | 445 | Pharmacyclics LLC.INDUSTRY | 19 | Mar 17, 2026 | clinicaltrials |
| NCT00006721 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | completed | Phase 3 | 571 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT05665348 | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy(TRIPLET) | completed | Phase 2 / Phase 3 | 229 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 | Mar 2, 2026 | clinicaltrials |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | completed | Phase 3 | 1,334 | TakedaINDUSTRY | 21 | Feb 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | completed | Phase 3 | 125 | Gamida Cell ltdINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT03976362 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | completed | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Feb 25, 2026 | clinicaltrials |
| NCT02684292 | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | completed | Phase 3 | 304 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 18, 2026 | clinicaltrials |
| NCT05804032 | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 514 | University of Heidelberg Medical CenterOTHER | 2 | Feb 18, 2026 | clinicaltrials |
| NCT06235099 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer(Solar-Recur) | completed | Phase 3 | 235 | Curium US LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04214444 | Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab(EVAPOR) | completed | Phase 3 | 26 | University Hospital, ToursOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT01358747 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL(AHL 2011) | completed | Phase 3 | — | Centre Hospitalier Universitaire DijonOTHER | 2 | Feb 9, 2026 | clinicaltrials |
| NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | completed | Phase 3 | 482 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 10 | Feb 9, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT03820986 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | completed | Phase 3 | 674 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Feb 9, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | completed | Phase 3 | 861 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT01730937 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | completed | Phase 3 | 193 | Radiation Therapy Oncology GroupNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT01983748 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | completed | Phase 3 | 200 | University Hospital ErlangenOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03284866 | HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV(COVENANT) | completed | Phase 3 | 536 | AIDS Malignancy ConsortiumNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT02750202 | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts(TheraVACCS) | completed | Phase 3 | 52 | University of PretoriaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04334759 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma(DREAM3R) | completed | Phase 3 | 214 | PrECOG, LLC.OTHER | 3 | Jan 22, 2026 | clinicaltrials |
| NCT03377491 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | completed | Phase 3 | 571 | NovoCure Ltd.INDUSTRY | 20 | Jan 21, 2026 | clinicaltrials |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06058793 | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 3 | 138 | Boehringer IngelheimINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT04655144 | Dexamethasone for Post Uterine Artery Embolization Pain(Dex-Fib) | completed | Phase 3 | 42 | University of MiamiOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT03594149 | Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients(AZABAC) | completed | Phase 3 | 60 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer(EL1SSAR) | completed | Phase 3 | 184 | Hoffmann-La RocheINDUSTRY | 13 | Dec 26, 2025 | clinicaltrials |
| NCT04889118 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | completed | Phase 3 | 131 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT00757302 | Intraoperative Gamma Camera for Breast Cancer Surgery | completed | Phase 3 | 110 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 19, 2026source: clinicaltrials